Skip to main content

SGIP21027 / Semaphorin 4D / Mulkerin

Basic Study Information

This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy. Phase 2 will assess the efficacy of this combination therapy.

Location: University of Rochester Medical Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Daniel Mulkerin

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search